Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cancer is one of the underlying diseases that increase the risk of COVID-19 developing to serious illness.

In cancer patients, categories at risk include:

• Patients receiving chemotherapy, or who have received chemotherapy in the last 3 months
• Patients receiving extensive radiotherapy
• People who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppressive drugs
• People with some types of blood or lymphatic system cancer which damage the immune system, even if they have not needed treatment (for example, chronic leukaemia, lymphoma or myeloma).

Specific risk groups are cancer patients with an impaired immune system such as:

• Leukocytopaenia
• Low immunoglobulin levels
• Long lasting immunosuppression (steroids, antibodies)

Journal of carcinogenesis & Mutagenesis is using Editorial Tracking System for quality in review process. Editorial Tracking is an online manuscript submission, review and tracking systems used by most of the best open access journals.

Review processing is performed by the editorial board members of carcinogenesis & Mutagenesis (Volume 11) or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript.

Authors are requested to submit their manuscripts as an e-mail attachment to mail

Our journal shares all the views and ideas about Cancer. If u has anything related to cancer patients during this COVID-19 pandemic era, you can contact us.

Best regards
Editorial Team
Journal of Carcinogenesis & Mutagenesis
NLM ID: 101612108